Urology

Your Article Summary

See Latest Articles

A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder
Urologic Oncology: Seminars and Original Investigations, 10/26/09

Satyam A et al. – The results of the study delineate that in bladder tumor patients a marked polarization exists towards the expression of Th2 type cytokines while Th1 remain suppressed. Furthermore, the levels of all the cytokines alter according to the grades of the tumor. This can give significant insights about the use of Th1 type cytokines for the administration of immunotherapy to bladder cancer patients. Development of new strategies attempting to manipulate the equilibrium between Th1 and Th2 cells would be beneficial in the management of UC of bladder in future.

Today in Bladder...keeping you current

Receive free subspecialty "5-minute updates" via email

Frequently asked questions in the evaluation and management of overactive bladder
The Journal of Family Practice, 11/02/09

Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/26/09

Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multicenter external validation study
Clinical Cancer Research, 11/17/09

See All of Bladder

Today in Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Is statin use associated with prostate cancer aggressiveness
BJU International, 11/09/09

Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09

Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/26/09

See All of Oncology